menu ☰
menu ˟

FRAME: Romosozumab reduces new vertebral fractures in postmenopausal women with osteoporosis

22 Sep 2016
In postmenopausal women with osteoporosis, the monoclonal antibody romosozumab was associated with a lower risk for new vertebral fractures vs. placebo at both 12 and 24 months, according to study data presented at the American Society for Bone and M...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.